Volume Spike Investor

Dendreon Corp. (NASDAQ: DNDN) is seeing a gap-up this morning after Citigroup started coverage of the prostate cancer PROVENGE owner with a BUY rating and a $35 price target.  Shares closed at $25.61 yesterday, and at 8:17 AM EST we have seen 35,000 shares trade hands.  The last price is $26.45.  As a reminder, the 52-week high is $27.40 and the high close is $25.74. -Jon Ogg